New drug combo tested in japanese lymphoma patients after other treatments fail
NCT ID NCT04542824
Summary
This trial is testing a drug called epcoritamab, alone or combined with standard treatments, for Japanese adults with B-cell lymphomas that have returned or not responded to prior therapy. The first part finds the safest and most effective dose. The second part treats more people to better understand how well the drug works and its side effects across different lymphoma types.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Aichi, Japan
-
Cancer Institute Hospital of JFCR
Tokyo, Japan
-
Fukushima Medical University Hospital
Fukushima, Japan
-
Kagoshima University Hospital
Kagoshima, Japan
-
Kindai University Hospital
Osaka, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Matsuyama Red Cross Hospital
Ehime, Japan
-
NHO Nagoya Medical Center
Aichi, Japan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
-
Osaka University Hospital
Osaka, Japan
-
Tohoku University Hoaspital
Sendai, Miyagi, 980-8577, Japan
-
Tokyo Medical University Hospital
Tokyo, Japan
-
Yamagata University Hospital
Yamagata, Japan
Conditions
Explore the condition pages connected to this study.